Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 10/20 | 0.61 |
| ▸ | ABCC9 | O60706 | 4/20 | 0.60 |
| ▸ | KCNE1 | P15382 | 3/20 | 0.58 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.58 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.56 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.56 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9185586 | 1.00 | KDM4E (0.62) | KDM4EABCB1ABCC9KCNE1KCNQ1 | |
| SCHEMBL9185591 | 1.00 | KDM4E (0.62) | KDM4EABCB1ABCC9KCNE1KCNQ1 | |
| SCHEMBL8090416 | 0.88 | KDM4E (0.56) | KDM4EABCB1ABCC9KCNE1KCNQ1 | |
| SCHEMBL8090417 | 0.88 | KDM4E (0.56) | KDM4EABCB1ABCC9KCNE1KCNQ1 | |
| SCHEMBL8076989 | 0.88 | KDM4E (0.56) | KDM4EABCB1ABCC9KCNE1KCNQ1 | |
| SCHEMBL8090414 | 0.88 | KDM4E (0.56) | KDM4EABCB1ABCC9KCNE1KCNQ1 | |
| SCHEMBL9210536 | 0.87 | KDM4E (0.55) | KDM4EABCB1ABCC9KCNE1KCNQ1 | |
| SCHEMBL9210524 | 0.87 | KDM4E (0.55) | KDM4EABCB1ABCC9KCNE1KCNQ1 | |
| SCHEMBL9210518 | 0.87 | KDM4E (0.55) | KDM4EABCB1ABCC9KCNE1KCNQ1 | |
| SCHEMBL12231590 | 0.86 | KDM4E (0.61) | KDM4EABCB1ABCC9KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937669-B9 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-18 | — | — | EP | disclosed |
| EP-1937669-B1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| US-7838553-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-23 | — | — | US | disclosed |
| US-7812183-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-12 | — | — | US | disclosed |
| EP-1940516-A2 | BENZOPYRAN AND PYRANOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | Janssen Pharmaceutica, N.V. (BE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1937669-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | US | disclosed |
| WO-2007027959-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027780-A2 | BENZOPYRAN AND PYRANOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-01 | — | — | US | disclosed |
| US-5478734-A | Intermediates in preparing potassium channel activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
| EP-0629702-A2 | Enzymatic preparation of chiral epoxide or hydroxy compounds by stereoselective epoxidation or hydroxylation | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | KDM4E 885/4885ABCB1 158/4885ABCC9 217/4885 |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | KDM4E 885/4885ABCB1 158/4885ABCC9 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.